US20180055020A1 - Mice With Transgene Of iBox Peptide Inhibitor Of Group B p21-Activated Kinases - Google Patents
Mice With Transgene Of iBox Peptide Inhibitor Of Group B p21-Activated Kinases Download PDFInfo
- Publication number
- US20180055020A1 US20180055020A1 US15/683,948 US201715683948A US2018055020A1 US 20180055020 A1 US20180055020 A1 US 20180055020A1 US 201715683948 A US201715683948 A US 201715683948A US 2018055020 A1 US2018055020 A1 US 2018055020A1
- Authority
- US
- United States
- Prior art keywords
- mouse
- nucleic acid
- acid sequence
- ibox
- transgene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700019146 Transgenes Proteins 0.000 title claims abstract description 88
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 40
- 239000003112 inhibitor Substances 0.000 title claims abstract description 30
- 241000699670 Mus sp. Species 0.000 title abstract description 38
- 102000006271 p21-Activated Kinases Human genes 0.000 title abstract description 5
- 108010058266 p21-Activated Kinases Proteins 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 43
- 238000011830 transgenic mouse model Methods 0.000 claims abstract description 41
- 210000000056 organ Anatomy 0.000 claims abstract description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 63
- 150000007523 nucleic acids Chemical group 0.000 claims description 63
- 210000001519 tissue Anatomy 0.000 claims description 38
- 210000000496 pancreas Anatomy 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 22
- 210000001161 mammalian embryo Anatomy 0.000 claims description 19
- 108700020796 Oncogene Proteins 0.000 claims description 17
- 238000009395 breeding Methods 0.000 claims description 16
- 230000001488 breeding effect Effects 0.000 claims description 16
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 14
- 108010051219 Cre recombinase Proteins 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000004075 alteration Effects 0.000 claims description 5
- 241000699660 Mus musculus Species 0.000 abstract description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 73
- 230000014509 gene expression Effects 0.000 description 36
- 101150036876 cre gene Proteins 0.000 description 32
- 230000000694 effects Effects 0.000 description 14
- 101150105104 Kras gene Proteins 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101100296200 Mus musculus Pak3 gene Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- 102100040775 CREB-regulated transcription coactivator 1 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000891939 Homo sapiens CREB-regulated transcription coactivator 1 Proteins 0.000 description 1
- 101000998526 Homo sapiens PAK4-inhibitor INKA1 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101100028435 Mus musculus Pacsin1 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000054108 human Inka1 Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C12N9/1088—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01018—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
- C12Y306/05002—Small monomeric GTPase (3.6.5.2)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present disclosure relates generally to the field of transgenic animals. More particularly, the present disclosure relates to transgenic mice comprising a peptide inhibitor of Group B p21-activated kinase (Pak), the iBox peptide, that is constitutively expressed, including tissue-specific expression.
- the present disclosure further relates to cells, tissues, and organs obtainable from such mice, and methods for producing such mice.
- the present disclosure provides a transgenic mouse comprising a transgene comprising a nucleic acid sequence encoding a peptide inhibitor of Group B p21-activated kinase (Pak), the iBox peptide, which may optionally be operably linked to glutathione S-transferase (GST) to facilitate detection of this inhibitor.
- the transgene may further encode a fluorescent marker such as eGFP.
- the transgene is stably integrated into the mouse genome, for example, into a chromosome.
- the iBox peptide is constitutively expressed in the transgenic mouse. The expression may be limited to a particular cell, tissue, or organ of interest.
- the cell, tissue, or organ of interest may include the skin, tongue, esophagus, stomach, intestine, colon, mesothelium, Schwann cells, brain, lung, heart, liver, pancreas, kidney, bladder, testes, thyroid, ovaries, skeletal muscle, bone, or other organ, cell, or tissue.
- the organ of interest is the pancreas.
- Cells, tissues, or organs comprising the transgene may be isolated from the transgenic mouse.
- the present disclosure provides a transgenic mouse comprising a transgene encoding the iBox peptide inhibitor.
- the transgene comprises the nucleic acid sequence of SEQ ID NO:1 (gaagcagaggactggacggcagccctgctgaacaggggccgcagtcggcagcccctggtgctaggggataactgattg ctgatttagttcacaattggatggagttgcctgaatga).
- the transgene comprises the nucleic acid sequence of SEQ ID NO:2 (atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgac acttaggaatatcagaagaaaaatatgaagagcatagtatgagcgcgatgaaggtgataaatggcgaaacaaaagatgaattgggatg gagtacccaatcaccttattatattgatggtgatgaaaattaacacacagtctatggccatcatacgttatatagctgacaagcacaacatgagg gtggagtccaaaagagcgtgcagagatacaatgctttgaaggagcggattggatcggtgatcgaaggattggatcggatcgggattggattggaaaattaaagagcgttgggtggattggaaggt
- the transgene further comprises the nucleic acid sequence of SEQ ID NO:3 (atggt gagcaagggcgaggagctgacaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagacagcgtgtcc ggcgagggcgagggcgatgccacctacggcaagctgaccctgaagacatctgcaccaccggcaagctgcccgtgccctggccaccc tcgtcgtggccaccc tcgtgtgtgccgctaccccgaccacatgaagcagcactttcagacttcttcaagtccgccatgcccga aggctacgtccaggagcccgaggctaggaggaccaccatcttctt
- the iBox transgene is expressed in one or more organs in the mouse. In some embodiments, the one or more organs includes the pancreas. In some embodiments, the iBox transgene is expressed only in the pancreas.
- the mouse may further comprise a transgene encoding a KRas oncogene, which KRas oncogene may be expressed only in the pancreas.
- the transgenic mouse may comprise the iBox transgene and a KRas oncogene transgene, both of which may be expressed in the pancreas of the mouse.
- the KRas oncogene may comprise one or more alterations and the KRas oncogene induces pancreatic cancer in the mouse.
- the present disclosure provides methods for producing a mouse comprising a transgene encoding the iBox peptide inhibitor.
- the methods comprise introducing a nucleic acid sequence encoding the iBox peptide inhibitor into a mouse egg, embryo, or embryonic stem cell, and transferring the mouse egg, embryo, or embryonic stem cell having the introduced nucleic acid sequence into a female mouse.
- the transgene comprises the nucleic acid sequence of SEQ ID NO:1.
- the transgene comprises the nucleic acid sequence of SEQ ID NO:2.
- the transgene further comprises the nucleic acid sequence of SEQ ID NO:3.
- the methods may further comprise breeding the female mouse and selecting offspring comprising the nucleic acid sequence.
- the female mouse may be bred, for example, with a male Cre mouse.
- the offspring may be selected according to their expression of the iBox peptide.
- the methods may further comprise breeding the selected offspring, for example, with a second (male or female) Cre mouse comprising a transgene encoding a KRas oncogene.
- the second Cre mouse expresses the KRas oncogene in the pancreas. Mice produced according to the inventive methods are also included.
- FIG. 1 panels A through E, show construction of an LSL-iBox knock-in vector and expected genomic organization in the mouse genome.
- Panel A shows an LR reaction performed between the pROSA26-DV1 vector and pEntry clone containing GST-iBox fragment to generate ROSA26 targeting vector.
- Panel B shows that homologous recombination occurred between exon 1 and 2 of wild-type ROSA26 locus in G4 ES cells after electroporation. Black boxes represent the exons located at ROSA26 locus.
- Panel C shows the genomic structure of the targeted allele.
- Panel D shows that the Cre-mediated deletion of intervening loxP flanked PGK-neo-3xpA (STOP) cassette results in the ROSA26-locus-based expression of an exonl-GST-iBox-IRES-eGFP bi-cistronic fusion transcript.
- Panel E shows genotyping PCR analysis of genomic DNA isolated from the tail detecting presence of fusion transcript by both external primers (F1 and R1) and internal primers (F2 and R2), verifying genomic organization of the LSL-iBox transgene.
- FIG. 2 shows the nucleic acid sequence of the pROSA26-Gst-iBox plasmid (circular plasmid, at 15,318 bp). Relevant sub-sections of the plasmid are designated.
- FIG. 3 shows a map of the pROSA26-Gst-iBox plasmid.
- FIG. 4 shows the expression of Gst-iBox in cells from transgenic mice.
- Mouse embryonic fibroblasts (MEFs) were established from an e13 embryo from a transgenic mouse (#7). These MEFs were transduced with an adenovirus encoding no insert ( ⁇ ) or the Cre gene (+) to remove the LSL cassette and permit Gst-iBox expression. 2 days post adenoviral infection, cell lysates were analyzed by immunoblot with anti-Gst antibodies.
- FIGS. 5A-5D show the expression of iBox and its effects on signaling.
- FIG. 5A mouse embryo fibroblasts (MEFs) derived from Tg-LSL-iBox mice were infected with an empty Adenovirus or Adenovirus-Cre. An anti-Gst blot is shown;
- FIG. 5B proliferation rates of MEFs expressing iBox (Cre+);
- FIG. 5C Pak4 was immunoprecipitated from lysates from these MEFs were assayed for Pak4 kinase activity; and
- FIG. 5D lysates were probed for the indicated signaling molecules.
- Cre mouse is a mouse that comprises a transgene encoding Cre recombinase (plural, “Cre mice”).
- the transgene may be expressed in one or more tissues or organs in the Cre mouse.
- a vector was designed to overexpress a peptide inhibitor of Group B Paks (Pak 4, Pak 5, and Pak 6) in mice.
- This peptide inhibitor termed iBox, is derived from amino acids 166 to 203 of the human INKA-1 protein.
- the iBox peptide transgene was linked to GST to facilitate detection upon expression. Transgene expression was restricted to a limited number of tissues in order to avoid the potential for wide-ranging, deleterious effects on development.
- This transgenic mouse model is designed such that mice constitutively express the iBox peptide.
- the transgene is compatible with the Cre-recombinase system.
- Cre-recombinase system for example, when a mouse comprising the iBox transgene is bred with a particular Cre recombinase-expressing mouse, the iBox peptide is expressed in the offspring.
- Cre-recombinase mice including mice with Cre-recombinase expression limited to particular tissues, it is possible to have tissue-specific expression of the iBox peptide. Accordingly, Group B Pak inhibition can be tissue specific.
- Tissue specificity may be useful, for example, in evaluating the role of Group B Paks in mouse development, tissue development, organ development, organ function, and system cross-talk. Tissue specificity may also be useful in evaluating disease, including cancer, diseases in which Group B Pak activity or impaired or inhibited activity is implicated, and other conditions that relate, directly or indirectly, to Group B Pak activity or impaired or inhibited activity.
- the transgenic mice allow the evaluation of the role of group B Paks in preclinical cancer models.
- Group B Paks may be conditionally inhibited in mice in any tissue at any time. This allows an assessment concerning the loss of Group B Pak activity, e.g., whether the loss may be beneficial in any condition, such as cancer.
- the iBox transgenic mouse continues to express endogenous group B Pak proteins, such that the expression of the iBox transgene will mimic the effects of a small molecule group B Pak inhibitor, thereby predicting drug effects on Pak 3, 4, and/or 5 inhibition.
- the iBox transgenic mouse model provides a better indicator of small molecule inhibitors than knock-outs or shRNA-expressing mice, as endogenous Pak proteins are still expressed.
- Group B Pak inhibition may be relevant to pancreatic cancer treatment.
- a model of Group B Pak inhibition in the pancreas may establish any one or combination of the Group B Paks as a druggable target.
- the survival of transgenic mice with the iBox peptide expressed in the pancreas is compared to control mice in which the iBox peptide is not expressed in the pancreas, or in which the iBox peptide is expressed in other tissue (aside from the pancreas).
- the iBox inhibitor is specific to Group B Paks (e.g., Pak 4, 5, and 6), and does not titrate out other binding partners, such as small GTPases, PIX, or Nck.
- Group B Paks e.g., Pak 4, 5, and 6
- expression of the iBox peptide is regulated by Cre recombinase in the mouse, thereby allowing flexibility in Pak inhibition in particular tissues and at particular times.
- An additional advantage is that the iBox inhibitor transgene is inserted as a single copy into a safe, well-characterized location in the genome (the ROSA26 locus), thus not disturbing expression of other mouse genes that may be key to continued viability of the mouse from conception through adulthood.
- ROSA26-promoter-based expression of the iBox transgene The ROSA26-promoter was selected for gene expression because it is known as a safe harbor site in the mouse genome, whereby insertion of the iBox transgene was not expected to not disrupt the expression of other genes of the mouse.
- a gateway enzyme mix (LR-clonase) is used to catalyze recombination between an entry clone (containing a gene of interest flanked by attL sites) and a destination vector (containing attR sites) to generate an expression clone. More specifically, the LR-clonase reaction can be used to insert the pROSA26-DV1 vector and pEntry clone containing GST-iBox (GST as reporter) fragment to generate ROSA26 targeting vector as shown in Panel B. Using this technique, homologous recombination occurred between exon 1 and 2 of wild-type ROSA26 locus in G4 ES cells after electroporation as shown in Panel B.
- the targeted allele comprises a fused GST-iBox gene sequence, as well as the reporter gene sequence, IRES-eGFP, as shown in Panel C.
- a Cre recombinase-mediated deletion of intervening loxP flanked PGK-neo-3xpA (STOP) cassette occurs in the ROSA26-locus-based expression of an exonl-GST-iBox-IRES-eGFP bi-cistronic fusion transcript.
- STOP loxP flanked PGK-neo-3xpA
- This deletion results from Cre-Lox recombinase technology at a site-specific location so that the GST-iBox gene sequence can be expressed.
- the system consists of a single enzyme, Cre recombinase, that recombines a pair of short target sequences, e.g., the Lox sequences, without the need to insert extra supporting proteins or sequences.
- Placing the Lox sequence appropriately flanking the PGK-neo-3xpA (STOP) cassette allows the genes to be deleted.
- STOP PGK-neo-3xpA
- the activity of the Cre recombinase enzyme can be controlled so that it is expressed in a particular cell type or triggered by an external stimulus like a chemical signal or a heat shock.
- the IRES-eGFP plasmid was used to confirm expression of GST-iBox plasmid.
- Viable GST-iBox transgenic mice can be produced, and these mice allow constitutive expression of a potent peptide inhibitor of Group B Paks (Pak 3, Pak 4, and Pak 5), iBox.
- the expression of the iBox transgene inhibited cell proliferation in each of the tissues studied.
- the iBox gene sequence is provided as SEQ ID NO:1, the GST-iBox gene sequence is shown in SEQ ID NO:2.
- the GST-iBox plasmid sequence is shown in FIG. 2 .
- the present disclosure provides iBox transgenic mice. This provides control of expression of the transgene in mice, and they may be useful as a tool to aid studies of development, tissue renewal, aging, cancer, and a variety of conditions or diseases that involve cell proliferation.
- a transgenic mouse comprises a transgene comprising a nucleic acid sequence encoding a peptide inhibitor of Group B Paks (Pak 4, Pak 5, and Pak 6), iBox.
- the mouse comprises a transgene comprising a nucleic acid sequence encoding the iBox peptide linked to GST.
- the mice comprise at least one copy of the transgene which, in some embodiments, is stably integrated into a chromosome.
- the transgene may be present in the gametes and/or somatic cells of the animal.
- the transgene may comprise the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or the complement thereof.
- the transgene may further comprise the nucleic acid sequence of SEQ ID NO:3 (eGFP).
- the iBox plasmid for transformation may comprise the plasmid shown in FIG. 2 and FIG. 3 .
- the transgene is present in and capable of expression in one or more tissues or organs in the mouse.
- tissues and organs include, but are not limited to, the skin, tongue, bone marrow, brain, heart, liver, kidney, lung, pancreas, bladder, mammary tissue, skeletal muscle, esophagus, stomach, small intestine, and large intestine, or any subpart thereof.
- Cells, tissues, or organs comprising the transgene may be isolated from the mouse, and may be grown in culture and/or subjected to further study.
- Cells, tissue, or organs comprising the iBox transgene e.g., SEQ ID NO:1 or SEQ ID NO:2 isolated or obtained from a mouse further are provided.
- a Cre mouse can include, but not be limited to, CDX2-Cre, Tie2-Cre, Postn-Cre, B6.FVB-Tg(Pdxl-cre)6Tuv/J (Pdx-Cre), in addition to others.
- Many Cre mice are commercially available, including many mice with particular tissues having Cre.
- Cre mice are suitable for breeding with the foxed iBox mouse in order to establish tissue-specific expression of the iBox transgene.
- Cre mice are available, for example, from The Jackson Laboratory (world wide web at jax.org). Constitutive expression of the transgene in particular tissues can thus be achieved through breeding with appropriate Cre mice.
- the Group B Paks may be expressed in any combination in a given tissue. Some tissues within the body express all three Group B Paks, though other tissues in the body express only one or two of these Group B Paks. As well, some tissues in the body may express more of a particular Group B Pak or combination thereof than another Group B Pak. Thus, for example, in embodiments where a given organ or tissue expresses only a single Group B Pak, the effects of the iBox inhibitor and, more generally, on inhibition of that Group B Pak can be assessed.
- mice can include any member of a category of other non-human mammals such as rodents (e.g., rats, rabbits), companion animals, farm animals, non-human primates, and other non-human mammals.
- rodents e.g., rats, rabbits
- companion animals e.g., farm animals, non-human primates, and other non-human mammals.
- Any non-human animal expressing Cre which can be bred with any non-human animal expressing a foxed iBox transgene, can produce iBox transgene expression.
- Mice being exemplified, are suitable.
- the present disclosure also provides methods for producing a transgenic mouse, as well as mice produced by any of the methods.
- the method comprises breeding a mouse comprising an iBox transgene (e.g., foxed iBox) with a Cre mouse, and selecting offspring having the iBox transgene and the CRE-expressing transgene. Such offspring should express the iBox peptide.
- an iBox transgene e.g., foxed iBox
- Cre mouse e.g., foxed iBox
- offspring should express the iBox peptide.
- the method comprises introducing a nucleic acid sequence encoding the iBox peptide inhibitor into a mouse egg (fertilized or unfertilized), zygote, embryo, or embryonic stem cell, and transferring the mouse egg, zygote, embryo, or embryonic stem cell having the introduced nucleic acid sequence into a female mouse.
- the method may further comprise fertilizing the egg.
- the method may further comprise breeding the female mouse and selecting offspring having the nucleic acid sequence. Offspring may be referred to as “progeny.”
- the method comprises introducing a nucleic acid sequence encoding iBox peptide inhibitor into a mouse egg (fertilized or unfertilized), zygote, embryo, or embryonic stem cell, transferring the mouse egg, zygote, embryo, or embryonic stem cell having the introduced nucleic acid sequence into a female mouse, breeding the female mouse with a male Cre mouse, and selecting offspring having the nucleic acid sequence and the CRE-expressing transgene, expressed in specific target tissues. Such offspring should express the iBox peptide in the target tissues.
- Any technique suitable for introducing the nucleic acid sequence may be used.
- Non-limiting examples include electroporation, microinjection, viruses, lipofection, calcium phosphate, and other known transformation techniques.
- Animals, including offspring, may be screened to confirm the presence of the transgene according to any technique suitable in the art. For example, cells may be isolated and tested for the presence of the gene, a detectable marker, selection marker, translation product, detectable mRNA, and/or detectable phenotype. Green fluorescent protein (GFP) or enhanced GFP (eGFP), or similar fluorescent marker, may be linked to or co-expressed with the iBox transgene to confirm presence, as well as expression of the transgene.
- the eGFP protein may comprise the protein encoded by the nucleic acid sequence of SEQ ID NO:3.
- Offspring carrying the transgene can further be bred with other animals to perpetuate the transgenic line, or can be bred with animals carrying other transgenes. Breeding includes back crossing, including back crossing into distinct genetic backgrounds. Offspring include any filial or backcross generation.
- offspring from the iBox+Cre mice can be further bred with a Cre-induced cancer model mouse.
- mice with a mutant KRAS transgene under loxP control can be bred with a Cre mouse comprising Cre in the pancreas, creating pancreas-specific expression of the mutant KRAS gene to induce mutant KRAS expression in the pancreas of progeny mice.
- the progeny mice will therefore develop pancreatic cancer.
- Such mutant-KRAS-expressing progeny mice can then be further bred with an iBox-expressing mouse, to determine the effect of Group B Pak inhibition (via the expressed iBox peptide) on KRAS-induced pancreatic cancer.
- a transgenic mouse comprising a transgene encoding the iBox peptide inhibitor.
- transgenic mouse according to embodiment 1, wherein the transgene comprises the nucleic acid sequence of SEQ ID NO:1.
- transgenic mouse according to embodiment 1 or 2, wherein the transgene comprises the nucleic acid sequence of SEQ ID NO:2.
- transgenic mouse according to any one of embodiments 1 to 3, wherein the transgene further comprises the nucleic acid sequence of SEQ ID NO:3.
- transgenic mouse according to any one of embodiments 1 to 4, wherein the transgene is inserted at the ROSA26 locus.
- transgenic mouse according to any one of embodiments 1 to 5, wherein the transgene is expressed in a single organ in the mouse.
- transgenic mouse according to embodiment 7, wherein the mouse further comprises a transgene encoding a KRas oncogene in the pancreas.
- a method for producing a mouse comprising a transgene encoding the iBox peptide inhibitor comprising introducing a nucleic acid sequence encoding the iBox peptide inhibitor into a mouse egg, embryo, or embryonic stem cell, and transferring the mouse egg, embryo, or embryonic stem cell having the introduced nucleic acid sequence into a female mouse.
- nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO:1.
- nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO:2.
- nucleic acid sequence further comprises the nucleic acid sequence of SEQ ID NO:3.
- a method for producing a mouse comprising a transgene encoding the iBox peptide inhibitor comprising introducing a nucleic acid sequence encoding the iBox peptide inhibitor into a mouse egg, embryo, or embryonic stem cell, and transferring the mouse egg, embryo, or embryonic stem cell having the introduced nucleic acid sequence into a female mouse, breeding the female mouse with a male Cre mouse, and selecting offspring expressing the iBox transgene.
- nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO:1.
- nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO:2.
- nucleic acid sequence further comprises the nucleic acid sequence of SEQ ID NO:3.
- the Gateway-compatible pROSA26-DV1 was obtained from Dr. Jody Haigh.
- a GST-iBox fragment was cloned into a pEntry vector after PCR and gel purification.
- the LR reaction was performed using ClonaseTM Enzyme Mix (Life Technology) according to the manufacture's instruction.
- a positive clone (pROSA26-GST-iBox-IRES-eGFP) was analyzed by restriction digests and sequencing.
- pROSA26-GST-iBox-IRES-eGFP was linearized by PvuI and electroporated into G4 ES cells.
- B6C3F1 female mice were superovulated with 5 iu of PMSG and 5 iu of hCG each, and mated to B6C3F1 males to generate 1-cell fertilized embryos for microinjection.
- ROSA26 L/R zinc finger nuclease mRNA 50 ng/ ⁇ l
- iBox DNA construct 2 ng/ ⁇ l
- the pROSA26-GST-iBox-IRES-eGFP plasmid was co-injected with Zinc-finger constructs targeting the Rosa26 locus into mouse zygotes.
- Zygotes were obtained by superovulation of C57BL/6N females (Charles River).
- the next day zygotes were collected from oviducts and microinjected in M2 embryo medium following standard procedures with a mixture of targeting vector and ZFNRosa mRNAs (2.5 ng/ ⁇ L each) loaded into a single microinjection needle.
- a two-step procedure was applied: A first aliquot of the DNA/RNA mixture was injected into the male pronucleus (to deliver the DNA vector, as used for the production of transgenic mice).
- a second aliquot of the DNA/RNA mixture was injected into the cytoplasm to deliver the ZFN mRNA directly to the translation machinery. Injections were performed using a Leica micromanipulator and microscope and an Eppendorf FemtoJet injection device. Injected zygotes were transferred into pseudopregnant CD1 female mice and fetuses recovered at day E18 for further analysis. Recovered fetuses were analyzed by PCR using the F1 and R1, and F2 and R2 primers to identify successfully targeted mice. Genomic DNA of pups was prepared from tails for detecting existence of transgene by both external primer (F1 and R1) and internal primer (F2 and R2).
- MEFs Primary mouse embryo fibroblasts were established from E14 embryos from pregnant ROSA26-iBox mice. Cell lines were maintained in DMEM medium supplemented with 10% of FBS, 2 mM L-glutamine and 100 Um′ penicillin/streptomycin ay 37° C. in a humidified 5% CO 2 incubator. To document iBox and EGFP expression, the MEFs were transduced with Adeno-Cre which removes the LSL cassette. MEFs were imaged to documents EGFP expression and lysates were probed by immunoblot to document iBox expression using anti-GST antibodies that recognize the GST protein that is fused to the N-terminus of iBox. These lysates were also probed with antibodies against Erk and P-Erk, Src and P-Src, Fak and P-Fak, as well as GAPDH.
- FIG. 5A shows mouse embryo fibroblasts (MEFs) derived from Tg-LSL-iBox mice were infected with an empty Adenovirus or Adenovirus-Cre. An anti-Gst blot is shown.
- FIG. 5B shows proliferation rates of MEFs expressing iBox (Cre+).
- Pak4 was immunoprecipitated from ROSA26-iBox MEFs and Protein-A-Pak4 beads were incubated with recombinant Pacsin or CRTC1 for 10 minutes at 30° C. in a buffer containing 50 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 , 1 mM DTT, and 50 ⁇ M ATP. Reactions were terminated with hot 6 ⁇ SDS/PAGE buffer and the samples were analyzed by immunoblot using anti-P-pacsin or anti-P-CRTC1 antibodies.
- FIG. 5C shows Pak4 was immunoprecipitated from lysates from these MEFs were assayed for Pak4 kinase activity.
- FIG. 5D shows lysates were probed for the indicated signaling molecules. Inhibition of Erk, Src, and Fak was observed.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application claims priority to U.S. Application No. 62/378,769, filed Aug. 24, 2016, which is incorporated herein by reference in its entirety.
- This invention was made with government support under Grant Nos. R01 CA142928 and R01 CA148805 awarded by the National Institutes of Health. The government has certain rights in the invention.
- The present disclosure relates generally to the field of transgenic animals. More particularly, the present disclosure relates to transgenic mice comprising a peptide inhibitor of Group B p21-activated kinase (Pak), the iBox peptide, that is constitutively expressed, including tissue-specific expression. The present disclosure further relates to cells, tissues, and organs obtainable from such mice, and methods for producing such mice.
- Various Pak knock-out mice have been made. These mice only remove single group A or group B Pak genes and, therefore, cannot serve as a model of inhibition of the full group of Paks. In addition, knock-out mice eliminate Pak's scaffold function in addition to eliminating its kinase function.
- The present disclosure provides a transgenic mouse comprising a transgene comprising a nucleic acid sequence encoding a peptide inhibitor of Group B p21-activated kinase (Pak), the iBox peptide, which may optionally be operably linked to glutathione S-transferase (GST) to facilitate detection of this inhibitor. The transgene may further encode a fluorescent marker such as eGFP. In some embodiments, the transgene is stably integrated into the mouse genome, for example, into a chromosome. In some embodiments, the iBox peptide is constitutively expressed in the transgenic mouse. The expression may be limited to a particular cell, tissue, or organ of interest. The cell, tissue, or organ of interest may include the skin, tongue, esophagus, stomach, intestine, colon, mesothelium, Schwann cells, brain, lung, heart, liver, pancreas, kidney, bladder, testes, thyroid, ovaries, skeletal muscle, bone, or other organ, cell, or tissue. In some embodiments, the organ of interest is the pancreas. Cells, tissues, or organs comprising the transgene may be isolated from the transgenic mouse. Thus, the present disclosure provides a transgenic mouse comprising a transgene encoding the iBox peptide inhibitor.
- In some embodiments, the transgene comprises the nucleic acid sequence of SEQ ID NO:1 (gaagcagaggactggacggcagccctgctgaacaggggccgcagtcggcagcccctggtgctaggggataactgattg ctgatttagttcacaattggatggagttgcctgaatga). In some embodiments, the transgene comprises the nucleic acid sequence of SEQ ID NO:2 (atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgac acttaggaatatcagaagaaaaatatgaagagcatagtatgagcgcgatgaaggtgataaatggcgaaacaaaaagatgaattgggatg gagtacccaatcaccttattatattgatggtgatgaaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgagg gtggagtccaaaagagcgtgcagagatacaatgcttgaaggagcggattggatattagatacggtgatcgagaattgcatatagtaaaga catgaaactctcaaagagattacttagcaagctacctgaaatgctgaaaatgacgaagatcgatatgtcataaaacatatttaaatggtgatc atgtaacccatcctgacttcatgagtatgacgctcagatgagattatacatggacccaatgtgcctggatgcgacccaaaattagatgatta aaaaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagcatggccatgcagggctggcaagccacgtag gtggtggcgaccatcctccaaaatcggatctggaccgcgtggatccgaagcagaggactggacggcagccctgctgaacaggggccgc agtcggcagcccctggtgctaggggataactgttttgctgatttagttcacaattggatggagttgcctgaatga). In some embodiments, the transgene further comprises the nucleic acid sequence of SEQ ID NO:3 (atggt gagcaagggcgaggagctgacaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagacagcgtgtcc ggcgagggcgagggcgatgccacctacggcaagctgaccctgaagacatctgcaccaccggcaagctgcccgtgccctggcccaccc tcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccga aggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctg gtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccaca acgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctc gccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctga gcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtac aagta). The transgene may be inserted at the ROSA26 locus.
- In some embodiments, the iBox transgene is expressed in one or more organs in the mouse. In some embodiments, the one or more organs includes the pancreas. In some embodiments, the iBox transgene is expressed only in the pancreas.
- The mouse may further comprise a transgene encoding a KRas oncogene, which KRas oncogene may be expressed only in the pancreas. Thus, the transgenic mouse may comprise the iBox transgene and a KRas oncogene transgene, both of which may be expressed in the pancreas of the mouse. The KRas oncogene may comprise one or more alterations and the KRas oncogene induces pancreatic cancer in the mouse.
- The present disclosure provides methods for producing a mouse comprising a transgene encoding the iBox peptide inhibitor. In general, the methods comprise introducing a nucleic acid sequence encoding the iBox peptide inhibitor into a mouse egg, embryo, or embryonic stem cell, and transferring the mouse egg, embryo, or embryonic stem cell having the introduced nucleic acid sequence into a female mouse. In some embodiments, the transgene comprises the nucleic acid sequence of SEQ ID NO:1. In some embodiments, the transgene comprises the nucleic acid sequence of SEQ ID NO:2. In some embodiments, the transgene further comprises the nucleic acid sequence of SEQ ID NO:3. The methods may further comprise breeding the female mouse and selecting offspring comprising the nucleic acid sequence. The female mouse may be bred, for example, with a male Cre mouse. Upon breeding the female mouse with a male Cre mouse, the offspring may be selected according to their expression of the iBox peptide. The methods may further comprise breeding the selected offspring, for example, with a second (male or female) Cre mouse comprising a transgene encoding a KRas oncogene. In some embodiments, the second Cre mouse expresses the KRas oncogene in the pancreas. Mice produced according to the inventive methods are also included.
-
FIG. 1 , panels A through E, show construction of an LSL-iBox knock-in vector and expected genomic organization in the mouse genome. Panel A shows an LR reaction performed between the pROSA26-DV1 vector and pEntry clone containing GST-iBox fragment to generate ROSA26 targeting vector. Panel B shows that homologous recombination occurred betweenexon -
FIG. 2 shows the nucleic acid sequence of the pROSA26-Gst-iBox plasmid (circular plasmid, at 15,318 bp). Relevant sub-sections of the plasmid are designated. -
FIG. 3 shows a map of the pROSA26-Gst-iBox plasmid. -
FIG. 4 shows the expression of Gst-iBox in cells from transgenic mice. Mouse embryonic fibroblasts (MEFs) were established from an e13 embryo from a transgenic mouse (#7). These MEFs were transduced with an adenovirus encoding no insert (−) or the Cre gene (+) to remove the LSL cassette and permit Gst-iBox expression. 2 days post adenoviral infection, cell lysates were analyzed by immunoblot with anti-Gst antibodies. -
FIGS. 5A-5D show the expression of iBox and its effects on signaling.FIG. 5A : mouse embryo fibroblasts (MEFs) derived from Tg-LSL-iBox mice were infected with an empty Adenovirus or Adenovirus-Cre. An anti-Gst blot is shown;FIG. 5B : proliferation rates of MEFs expressing iBox (Cre+);FIG. 5C : Pak4 was immunoprecipitated from lysates from these MEFs were assayed for Pak4 kinase activity; andFIG. 5D : lysates were probed for the indicated signaling molecules. - Various terms relating to embodiments of the present disclosure are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art, unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definition provided herein.
- As used herein, the singular forms “a,” “an,” and “the” include plural referents unless expressly stated otherwise.
- As used herein, “Cre mouse” is a mouse that comprises a transgene encoding Cre recombinase (plural, “Cre mice”). The transgene may be expressed in one or more tissues or organs in the Cre mouse.
- In order to determine the effects of inhibiting the Group B p21-activated kinases (Paks) in vivo, a vector was designed to overexpress a peptide inhibitor of Group B Paks (
Pak 4,Pak 5, and Pak 6) in mice. This peptide inhibitor, termed iBox, is derived from amino acids 166 to 203 of the human INKA-1 protein. The iBox peptide transgene was linked to GST to facilitate detection upon expression. Transgene expression was restricted to a limited number of tissues in order to avoid the potential for wide-ranging, deleterious effects on development. - This transgenic mouse model is designed such that mice constitutively express the iBox peptide. In some embodiments, the transgene is compatible with the Cre-recombinase system. Thus, for example, when a mouse comprising the iBox transgene is bred with a particular Cre recombinase-expressing mouse, the iBox peptide is expressed in the offspring. As there are many Cre-recombinase mice available, including mice with Cre-recombinase expression limited to particular tissues, it is possible to have tissue-specific expression of the iBox peptide. Accordingly, Group B Pak inhibition can be tissue specific. Tissue specificity may be useful, for example, in evaluating the role of Group B Paks in mouse development, tissue development, organ development, organ function, and system cross-talk. Tissue specificity may also be useful in evaluating disease, including cancer, diseases in which Group B Pak activity or impaired or inhibited activity is implicated, and other conditions that relate, directly or indirectly, to Group B Pak activity or impaired or inhibited activity.
- The transgenic mice allow the evaluation of the role of group B Paks in preclinical cancer models. Group B Paks may be conditionally inhibited in mice in any tissue at any time. This allows an assessment concerning the loss of Group B Pak activity, e.g., whether the loss may be beneficial in any condition, such as cancer. Unlike Pak-knock-out mice, the iBox transgenic mouse continues to express endogenous group B Pak proteins, such that the expression of the iBox transgene will mimic the effects of a small molecule group B Pak inhibitor, thereby predicting drug effects on
Pak - For example, it is believed that Group B Pak inhibition may be relevant to pancreatic cancer treatment. Accordingly, a model of Group B Pak inhibition in the pancreas may establish any one or combination of the Group B Paks as a druggable target. The survival of transgenic mice with the iBox peptide expressed in the pancreas is compared to control mice in which the iBox peptide is not expressed in the pancreas, or in which the iBox peptide is expressed in other tissue (aside from the pancreas).
- It is believed that the iBox inhibitor is specific to Group B Paks (e.g.,
Pak FIG. 1 , panels A through E, describes an exemplary embodiment of the generation of the ROSA26-promoter-based expression of the iBox transgene. The ROSA26-promoter was selected for gene expression because it is known as a safe harbor site in the mouse genome, whereby insertion of the iBox transgene was not expected to not disrupt the expression of other genes of the mouse. - Generally, a gateway enzyme mix (LR-clonase) is used to catalyze recombination between an entry clone (containing a gene of interest flanked by attL sites) and a destination vector (containing attR sites) to generate an expression clone. More specifically, the LR-clonase reaction can be used to insert the pROSA26-DV1 vector and pEntry clone containing GST-iBox (GST as reporter) fragment to generate ROSA26 targeting vector as shown in Panel B. Using this technique, homologous recombination occurred between
exon - During recombination, a Cre recombinase-mediated deletion of intervening loxP flanked PGK-neo-3xpA (STOP) cassette occurs in the ROSA26-locus-based expression of an exonl-GST-iBox-IRES-eGFP bi-cistronic fusion transcript. This deletion results from Cre-Lox recombinase technology at a site-specific location so that the GST-iBox gene sequence can be expressed. The system consists of a single enzyme, Cre recombinase, that recombines a pair of short target sequences, e.g., the Lox sequences, without the need to insert extra supporting proteins or sequences. Placing the Lox sequence appropriately flanking the PGK-neo-3xpA (STOP) cassette allows the genes to be deleted. As a result, the activity of the Cre recombinase enzyme can be controlled so that it is expressed in a particular cell type or triggered by an external stimulus like a chemical signal or a heat shock. These targeted DNA changes are useful in cell lineage tracing and when mutants are lethal if expressed globally.
- Genotyping using PCR analysis of genomic DNA isolated from tail detecting presence of fusion transcript by both external primers (F1 and R1) and internal primers (F2 and R2). These primers are as follows:
-
(SEQ ID NO: 4) F1: 5′-TAGGTAGGGGATCGGGACTCT-3′; (SEQ ID NO: 5) R1: 5′-GCGAAGAGTTTGTCCTCAACC-3′; (SEQ ID NO: 6) F2: 5′-CCCATCAAGCTGATCCGGAAC-3′; and (SEQ ID NO: 7) R2: 5′-GTGAACAGCTCCTCGCCCTTG-3′. - These primers were used to confirm expression of the GST-iBox gene sequence in vitro and in vivo. The IRES-eGFP plasmid was used to confirm expression of GST-iBox plasmid. Viable GST-iBox transgenic mice can be produced, and these mice allow constitutive expression of a potent peptide inhibitor of Group B Paks (
Pak 3,Pak 4, and Pak 5), iBox. In preliminary experiments, the expression of the iBox transgene inhibited cell proliferation in each of the tissues studied. The iBox gene sequence is provided as SEQ ID NO:1, the GST-iBox gene sequence is shown in SEQ ID NO:2. The GST-iBox plasmid sequence is shown inFIG. 2 . - The present disclosure provides iBox transgenic mice. This provides control of expression of the transgene in mice, and they may be useful as a tool to aid studies of development, tissue renewal, aging, cancer, and a variety of conditions or diseases that involve cell proliferation.
- In one aspect, a transgenic mouse comprises a transgene comprising a nucleic acid sequence encoding a peptide inhibitor of Group B Paks (
Pak 4,Pak 5, and Pak 6), iBox. In some embodiments, the mouse comprises a transgene comprising a nucleic acid sequence encoding the iBox peptide linked to GST. The mice comprise at least one copy of the transgene which, in some embodiments, is stably integrated into a chromosome. The transgene may be present in the gametes and/or somatic cells of the animal. The transgene may comprise the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or the complement thereof. The transgene may further comprise the nucleic acid sequence of SEQ ID NO:3 (eGFP). The iBox plasmid for transformation may comprise the plasmid shown inFIG. 2 andFIG. 3 . - In some embodiments, the transgene is present in and capable of expression in one or more tissues or organs in the mouse. Exemplary tissues and organs include, but are not limited to, the skin, tongue, bone marrow, brain, heart, liver, kidney, lung, pancreas, bladder, mammary tissue, skeletal muscle, esophagus, stomach, small intestine, and large intestine, or any subpart thereof. Cells, tissues, or organs comprising the transgene may be isolated from the mouse, and may be grown in culture and/or subjected to further study. Cells, tissue, or organs comprising the iBox transgene (e.g., SEQ ID NO:1 or SEQ ID NO:2) isolated or obtained from a mouse further are provided.
- It is possible to achieve tissue-specific (and organ-specific) expression of the iBox transgene, for example, by breeding the foxed iBox mouse with a Cre mouse having the Cre recombinase gene expressed in particular tissues or organs. An example of expression of the iBox transgene following Cre-mediated excision of the LSL motif is shown in
FIG. 4 . For example, a Cre mouse can include, but not be limited to, CDX2-Cre, Tie2-Cre, Postn-Cre, B6.FVB-Tg(Pdxl-cre)6Tuv/J (Pdx-Cre), in addition to others. Many Cre mice are commercially available, including many mice with particular tissues having Cre. Any such Cre mice are suitable for breeding with the foxed iBox mouse in order to establish tissue-specific expression of the iBox transgene. Cre mice are available, for example, from The Jackson Laboratory (world wide web at jax.org). Constitutive expression of the transgene in particular tissues can thus be achieved through breeding with appropriate Cre mice. - The Group B Paks (
Pak - The present disclosure is not limited to mice, and can include any member of a category of other non-human mammals such as rodents (e.g., rats, rabbits), companion animals, farm animals, non-human primates, and other non-human mammals. Any non-human animal expressing Cre, which can be bred with any non-human animal expressing a foxed iBox transgene, can produce iBox transgene expression. Mice, being exemplified, are suitable.
- The present disclosure also provides methods for producing a transgenic mouse, as well as mice produced by any of the methods. In some embodiments, the method comprises breeding a mouse comprising an iBox transgene (e.g., foxed iBox) with a Cre mouse, and selecting offspring having the iBox transgene and the CRE-expressing transgene. Such offspring should express the iBox peptide.
- In some embodiments, the method comprises introducing a nucleic acid sequence encoding the iBox peptide inhibitor into a mouse egg (fertilized or unfertilized), zygote, embryo, or embryonic stem cell, and transferring the mouse egg, zygote, embryo, or embryonic stem cell having the introduced nucleic acid sequence into a female mouse. The method may further comprise fertilizing the egg. The method may further comprise breeding the female mouse and selecting offspring having the nucleic acid sequence. Offspring may be referred to as “progeny.”
- In some embodiments, the method comprises introducing a nucleic acid sequence encoding iBox peptide inhibitor into a mouse egg (fertilized or unfertilized), zygote, embryo, or embryonic stem cell, transferring the mouse egg, zygote, embryo, or embryonic stem cell having the introduced nucleic acid sequence into a female mouse, breeding the female mouse with a male Cre mouse, and selecting offspring having the nucleic acid sequence and the CRE-expressing transgene, expressed in specific target tissues. Such offspring should express the iBox peptide in the target tissues.
- Any technique suitable for introducing the nucleic acid sequence may be used. Non-limiting examples include electroporation, microinjection, viruses, lipofection, calcium phosphate, and other known transformation techniques.
- Animals, including offspring, may be screened to confirm the presence of the transgene according to any technique suitable in the art. For example, cells may be isolated and tested for the presence of the gene, a detectable marker, selection marker, translation product, detectable mRNA, and/or detectable phenotype. Green fluorescent protein (GFP) or enhanced GFP (eGFP), or similar fluorescent marker, may be linked to or co-expressed with the iBox transgene to confirm presence, as well as expression of the transgene. The eGFP protein may comprise the protein encoded by the nucleic acid sequence of SEQ ID NO:3.
- Offspring carrying the transgene can further be bred with other animals to perpetuate the transgenic line, or can be bred with animals carrying other transgenes. Breeding includes back crossing, including back crossing into distinct genetic backgrounds. Offspring include any filial or backcross generation.
- In some embodiments, offspring from the iBox+Cre mice (e.g., mice expressing the iBox transgene) can be further bred with a Cre-induced cancer model mouse. For example, mice with a mutant KRAS transgene under loxP control can be bred with a Cre mouse comprising Cre in the pancreas, creating pancreas-specific expression of the mutant KRAS gene to induce mutant KRAS expression in the pancreas of progeny mice. The progeny mice will therefore develop pancreatic cancer. Such mutant-KRAS-expressing progeny mice can then be further bred with an iBox-expressing mouse, to determine the effect of Group B Pak inhibition (via the expressed iBox peptide) on KRAS-induced pancreatic cancer.
- The following representative embodiments are presented:
- A transgenic mouse, comprising a transgene encoding the iBox peptide inhibitor.
- The transgenic mouse according to
embodiment 1, wherein the transgene comprises the nucleic acid sequence of SEQ ID NO:1. - The transgenic mouse according to
embodiment - The transgenic mouse according to any one of
embodiments 1 to 3, wherein the transgene further comprises the nucleic acid sequence of SEQ ID NO:3. - The transgenic mouse according to any one of
embodiments 1 to 4, wherein the transgene is inserted at the ROSA26 locus. - The transgenic mouse according to any one of
embodiments 1 to 5, wherein the transgene is expressed in a single organ in the mouse. - The transgenic mouse according to
embodiment 6, wherein the organ is the pancreas. - The transgenic mouse according to
embodiment 7, wherein the mouse further comprises a transgene encoding a KRas oncogene in the pancreas. - The transgenic mouse according to embodiment 8, wherein the KRas oncogene comprises one or more alterations.
- A cell isolated from the transgenic mouse according to any one of
embodiments 1 to 9, wherein the cell comprises the transgene. - A tissue isolated from the transgenic mouse according to any one of
embodiments 1 to 9, wherein at least one cell in the tissue comprises the transgene. - An organ isolated from the transgenic mouse according to any one of
embodiments 1 to 9, wherein at least one cell in the organ comprises the transgene. - The organ according to embodiment 12, wherein the organ is the pancreas.
- A method for producing a mouse comprising a transgene encoding the iBox peptide inhibitor, comprising introducing a nucleic acid sequence encoding the iBox peptide inhibitor into a mouse egg, embryo, or embryonic stem cell, and transferring the mouse egg, embryo, or embryonic stem cell having the introduced nucleic acid sequence into a female mouse.
- The method according to embodiment 14, wherein the nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO:1.
- The method according to
embodiment 14 or 15, wherein the nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO:2. - The method according to any one of embodiments 14 to 16, wherein the nucleic acid sequence further comprises the nucleic acid sequence of SEQ ID NO:3.
- The method according to any one of embodiments 14 to 17, further comprising breeding the female mouse and selecting offspring having the nucleic acid sequence.
- A mouse produced according to the methods of any one of embodiments 14 to 18.
- A method for producing a mouse comprising a transgene encoding the iBox peptide inhibitor, comprising introducing a nucleic acid sequence encoding the iBox peptide inhibitor into a mouse egg, embryo, or embryonic stem cell, and transferring the mouse egg, embryo, or embryonic stem cell having the introduced nucleic acid sequence into a female mouse, breeding the female mouse with a male Cre mouse, and selecting offspring expressing the iBox transgene.
- The method according to
embodiment 20, wherein the nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO:1. - The method according to
embodiment 20 or 21, wherein the nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO:2. - The method according to any one of
embodiments 20 to 22, wherein the nucleic acid sequence further comprises the nucleic acid sequence of SEQ ID NO:3. - The method according to any one of
embodiments 20 to 23, wherein the male Cre mouse expresses Cre recombinase in a single organ. - The method according to embodiment 24, wherein the single organ is the pancreas.
- The method according to any one of
embodiments 20 to 25, further comprising breeding the offspring with a second Cre mouse comprising a transgene encoding a KRas oncogene. - The method according to embodiment 26, wherein the second Cre mouse expresses the KRas oncogene in the pancreas.
- The method according to embodiment 26 or 27, wherein the KRas oncogene comprises one or more alterations.
- A mouse produced according to the methods of any one of
embodiments 20 to 28. - The following examples are provided to describe the present disclosure in greater detail. They are intended to illustrate, not to limit, the present disclosure.
- The Gateway-compatible pROSA26-DV1 was obtained from Dr. Jody Haigh. A GST-iBox fragment was cloned into a pEntry vector after PCR and gel purification. The LR reaction was performed using Clonase™ Enzyme Mix (Life Technology) according to the manufacture's instruction. A positive clone (pROSA26-GST-iBox-IRES-eGFP) was analyzed by restriction digests and sequencing. In particular, pROSA26-GST-iBox-IRES-eGFP was linearized by PvuI and electroporated into G4 ES cells.
- B6C3F1 female mice were superovulated with 5 iu of PMSG and 5 iu of hCG each, and mated to B6C3F1 males to generate 1-cell fertilized embryos for microinjection. ROSA26 L/R zinc finger nuclease mRNA (50 ng/μl) and iBox DNA construct (2 ng/μl) were injected into the embryos' pronuclei. The surviving embryos were implanted into d0.5 pseudo-pregnant recipient mothers (Swiss Webster).
- The pROSA26-GST-iBox-IRES-eGFP plasmid was co-injected with Zinc-finger constructs targeting the Rosa26 locus into mouse zygotes. Zygotes were obtained by superovulation of C57BL/6N females (Charles River). The next day zygotes were collected from oviducts and microinjected in M2 embryo medium following standard procedures with a mixture of targeting vector and ZFNRosa mRNAs (2.5 ng/μL each) loaded into a single microinjection needle. For microinjection a two-step procedure was applied: A first aliquot of the DNA/RNA mixture was injected into the male pronucleus (to deliver the DNA vector, as used for the production of transgenic mice). Upon the withdrawal of the injection needle from the pronucleus, a second aliquot of the DNA/RNA mixture was injected into the cytoplasm to deliver the ZFN mRNA directly to the translation machinery. Injections were performed using a Leica micromanipulator and microscope and an Eppendorf FemtoJet injection device. Injected zygotes were transferred into pseudopregnant CD1 female mice and fetuses recovered at day E18 for further analysis. Recovered fetuses were analyzed by PCR using the F1 and R1, and F2 and R2 primers to identify successfully targeted mice. Genomic DNA of pups was prepared from tails for detecting existence of transgene by both external primer (F1 and R1) and internal primer (F2 and R2).
- Primary mouse embryo fibroblasts were established from E14 embryos from pregnant ROSA26-iBox mice. Cell lines were maintained in DMEM medium supplemented with 10% of FBS, 2 mM L-glutamine and 100 Um′ penicillin/streptomycin ay 37° C. in a humidified 5% CO2 incubator. To document iBox and EGFP expression, the MEFs were transduced with Adeno-Cre which removes the LSL cassette. MEFs were imaged to documents EGFP expression and lysates were probed by immunoblot to document iBox expression using anti-GST antibodies that recognize the GST protein that is fused to the N-terminus of iBox. These lysates were also probed with antibodies against Erk and P-Erk, Src and P-Src, Fak and P-Fak, as well as GAPDH.
- Cells were plated at 2×103 in 96-well plates and 10 μl of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) solution was added to each well to a final concentration of 0.5 mg/ml. The reaction was stopped after 4 hours at 37° C. by adding 100 μl of solubilization solution (10% SDS in 0.01M HCl) and the samples were analyzed at 595 nm on Perkin Elmer Envision plate reader. Triplicates were performed for each sample, and experiments were performed on three occasions.
FIG. 5A shows mouse embryo fibroblasts (MEFs) derived from Tg-LSL-iBox mice were infected with an empty Adenovirus or Adenovirus-Cre. An anti-Gst blot is shown.FIG. 5B shows proliferation rates of MEFs expressing iBox (Cre+). - To analyze endogenous Pak4 activity, Pak4 was immunoprecipitated from ROSA26-iBox MEFs and Protein-A-Pak4 beads were incubated with recombinant Pacsin or CRTC1 for 10 minutes at 30° C. in a buffer containing 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM DTT, and 50 μM ATP. Reactions were terminated with hot 6×SDS/PAGE buffer and the samples were analyzed by immunoblot using anti-P-pacsin or anti-P-CRTC1 antibodies.
FIG. 5C shows Pak4 was immunoprecipitated from lysates from these MEFs were assayed for Pak4 kinase activity.FIG. 5D shows lysates were probed for the indicated signaling molecules. Inhibition of Erk, Src, and Fak was observed. - The present disclosure is not limited to the embodiments described and exemplified above, but is capable of variation and modification within the scope of the appended claims.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/683,948 US11240996B2 (en) | 2016-08-24 | 2017-08-23 | Mice with transgene of iBox peptide inhibitor of group B p21-activated kinases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662378769P | 2016-08-24 | 2016-08-24 | |
US15/683,948 US11240996B2 (en) | 2016-08-24 | 2017-08-23 | Mice with transgene of iBox peptide inhibitor of group B p21-activated kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180055020A1 true US20180055020A1 (en) | 2018-03-01 |
US11240996B2 US11240996B2 (en) | 2022-02-08 |
Family
ID=61240142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/683,948 Active US11240996B2 (en) | 2016-08-24 | 2017-08-23 | Mice with transgene of iBox peptide inhibitor of group B p21-activated kinases |
Country Status (1)
Country | Link |
---|---|
US (1) | US11240996B2 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10584353B2 (en) * | 2016-05-19 | 2020-03-10 | Institute For Cancer Research | P21-activated kinase inhibitor domain targeted transgenic mouse |
-
2017
- 2017-08-23 US US15/683,948 patent/US11240996B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11240996B2 (en) | 2022-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11089765B2 (en) | Genetically modified rat models for severe combined immunodeficiency (SCID) | |
ES2901074T3 (en) | Methods and compositions for targeted genetic modifications and methods of use | |
Druckenbrod et al. | Targeting of endothelin receptor‐B to the neural crest | |
US20160186208A1 (en) | Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal | |
JP6998656B2 (en) | lincRNA deletion non-human animal | |
Sodhi et al. | Generation of mice harbouring a conditional loss-of-function allele of Gata6 | |
US7582741B2 (en) | Conditional disruption of dicer1 in cell lines and non-human mammals | |
JP5075641B2 (en) | Genetically modified animals and uses thereof | |
US11240996B2 (en) | Mice with transgene of iBox peptide inhibitor of group B p21-activated kinases | |
ES2209650B2 (en) | NON-HUMAN MAMMALS DEFICIENT MUTANTS IN SIGMA RECEIVERS AND THEIR APPLICATIONS. | |
JP2001211782A (en) | Tob gene deletion knock out non-human mammal | |
US20200239907A1 (en) | P21-Activated Kinase Inhibitor Domain Targeted Transgenic Mouse | |
US9295239B2 (en) | MO-1 conditional knock-out non-human animal and uses thereof | |
KR101348852B1 (en) | Mis18α knockout mouse model and producing method thereof | |
US7518033B2 (en) | Methods for the production of cells and mammals with desired genetic modifications | |
US8835711B2 (en) | ANF-RGC in-gene knock-out animal | |
JP4374438B2 (en) | lab8a gene-deficient mouse | |
O’Connor et al. | Generating Conditional Mutants to Analyze Ciliary Functions: The Use of Cre–Lox Technology to Disrupt Cilia in Specific Organs | |
US20130318645A1 (en) | Methods and Vectors for Gene Targeting With Inducible Specific Expression | |
JP4940477B2 (en) | OASIS gene-deficient mouse | |
US8946503B2 (en) | hnRNP A1 knockout animal model and use thereof | |
JP6151502B2 (en) | Neuroblastoma model mouse | |
JPWO2008062904A1 (en) | Methods that enable stable expression of transgenes | |
JP2006325452A (en) | Tzf/tzf-l gene knockout non-human mammal, method for preparation of the same and method for using the same | |
JP2008061557A (en) | Mouse with neuron-specific expression of crerecombinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHERNOFF, JONATHAN;CHOW, HOI YEE;REEL/FRAME:043841/0445 Effective date: 20171010 Owner name: INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH I Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHERNOFF, JONATHAN;CHOW, HOI YEE;REEL/FRAME:043841/0445 Effective date: 20171010 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |